SCHEMBL30337392

SCHEMBL30337392

O=C1C2CN(Cc3ccc(-c4ccccc4)cc3)CCN2C(=O)CN1Cc1ccccn1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.44
▸ TSHR P16473 2/20 0.44
▸ KDM4E B2RXH2 5/20 0.43
▸ MAPT P10636 3/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ EGLN1 Q9GZT9 1/20 0.41
▸ ENPP2 Q13822 1/20 0.41
▸ LMNA P02545 2/20 0.40
▸ POLB P06746 1/20 0.39
▸ DDB1 Q16531 1/20 0.38
▸ CRBN Q96SW2 1/20 0.38
▸ SIGMAR1 Q99720 1/20 0.38
▸ CCR5 P51681 2/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24145803 0.88 ENPP2 (0.48) ALDH1A1TSHRENPP2CCR5CYP2D6
SCHEMBL30337246 0.87 ENPP2 (0.47) ENPP2CCR5CYP2D6L3MBTL1SMN1; SMN2
SCHEMBL30337139 0.86 MCHR1 (0.42) LMNADDB1CRBN
SCHEMBL24145684 0.83 FAAH (0.39) ALDH1A1TSHRENPP2CCR5CYP2D6
SCHEMBL30337200 0.83 FAAH (0.39) ALDH1A1TSHRENPP2CCR5CYP2D6
SCHEMBL30337505 0.83 ALDH1A1 (0.46) ALDH1A1KDM4EMAPTMAPK1ENPP2
SCHEMBL30337153 0.82 FAAH (0.48) EGLN1
SCHEMBL30337582 0.81 SMN1; SMN2 (0.45) TSHRPOLBSIGMAR1CYP2D6L3MBTL1
SCHEMBL30337060 0.81 KMT2A (0.49) ENPP2
SCHEMBL30337191 0.79 HTR1A (0.47) TSHRENPP2SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115916206-A Novel compound and pharmaceutical composition for preventing or treating resistant cancer comprising same 治愈医药社株式会社 2023-04-04 — — CN disclosed
Send feedback